| Size | Price | Stock | Qty |
|---|---|---|---|
| 500μg |
|
||
| 1mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
Lup-20(29)-en-28-oic acid, 2,3-dihydroxy- targets various cellular pathways involved in inflammation and cancer. It has been shown to inhibit topoisomerase and induce apoptosis in cancer cells. The compound also modulates inflammatory signaling pathways.
|
|---|---|
| ln Vitro |
Inducing apoptosis and inhibiting Akt–NF-κB signaling, Aophitolic Acid (0-30 µM; 72 hours; HSC-3, SCC2095, and SCC4 cells) exhibits dose-dependent antiproliferative action in oral cancer cells [1]. In SCC4 cells, Aophitolic Acid (0-25 µM; 3-72 hours) activates autophagy and upregulates the expression of two autophagy regulatory proteins and the autophagosome marker LC3B-II [1]. Aophitolic Acid (0-25 µM; 72 hours; SCC4 cells) decreases the expression of the oncogenic E3 ligase MDM2, while increasing p53 phosphorylation and expression [1]. With IC50 values of 17.6 and 22.7 µM, respectively, alphitolic acid (Aophitolic Acid) (0-25 µM; 72 hours; RAW 264.7 macrophages) possesses anti-inflammatory activity and inhibits the production of NO and TNF-α [2].
In vitro, lup-20(29)-en-28-oic acid, 2,3-dihydroxy- exhibits antiproliferative activity against various cancer cell lines. It induces apoptosis and inhibits cell migration. The compound also shows anti-inflammatory activity by reducing cytokine production. |
| ln Vivo |
In vivo anti-inflammatory action of aophitolic acid (47-756 µg/ear; ih; adult male CF-1 mice) has been shown [3].
In vivo, lup-20(29)-en-28-oic acid, 2,3-dihydroxy- has been studied in animal models of cancer and inflammation. It shows efficacy in reducing tumor growth and inflammation. The compound is a natural product with potential therapeutic applications. |
| Enzyme Assay |
In vitro enzyme assays measure the inhibition of topoisomerase or other enzymes by lup-20(29)-en-28-oic acid, 2,3-dihydroxy-. The compound is incubated with the enzyme and a substrate, and enzyme activity is measured. The IC50 is determined from dose-response curves.
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: HSC-3, SCC2095 and SCC4 Cell Tested Concentrations: 0, 10, 15, 20, 25 and 30 µM Incubation Duration: 72 hrs (hours) Experimental Results: Inhibited proliferation of SCC4 and SCC2095 cells with IC50 values respectively are 12 and 15 µM. Apoptosis analysis[1] Cell Types: SCC4 Cell Tested Concentrations: 0, 10, 20 and 30 µM Incubation Duration: 72 hrs (hours) Experimental Results: The percentage of apoptotic cells increased from 11.8% to 25.1% in a dose-dependent manner. Western Blot Analysis[1] Cell Types: SCC4 Cell Tested Concentrations: 0, 10, 15 and 20 µM Incubation Duration: 72 hrs (hours) Experimental Results: diminished expression of phosphorylated Akt and its downstream substrates including p70S6K, S6 and IκBα. Downregulates the expression of NF-κB and its downstream target gene product Bcl-2. Western Blot Analysis[1] Cell Types: SCC4 Cell Tested Concentrations: 0, 10, 15, 20 and 25 µM Incubation Duration: 3, 6, 12, 24, 48 and 72 hrs (hours) Experimental Results: Autophagosome marker LC3B-II in dose Add time-related methods. The expression of autophagy-related protei In vitro cellular assays evaluate the antiproliferative and apoptotic effects of lup-20(29)-en-28-oic acid, 2,3-dihydroxy- on cancer cell lines. Cells are treated with the compound, and cell viability is assessed using MTT or similar assays. Apoptosis is detected by Annexin V staining or caspase activity assays. |
| Animal Protocol |
Animal/Disease Models: Adult male CF-1 mice [3] Doses: 47, 94, 330, 378 and 756 µg/ear
Route of Administration: subcutaneous injection Experimental Results: Dose-dependent anti-inflammatory activity with ED50 of 0.11 and 0.20 µM . In vivo animal experiments are conducted in mouse xenograft models of cancer or in models of inflammation. Lup-20(29)-en-28-oic acid, 2,3-dihydroxy- is administered, and tumor growth or inflammation is assessed. |
| ADME/Pharmacokinetics |
Lup-20(29)-en-28-oic acid, 2,3-dihydroxy- has a molecular formula of C30H48O4 and a molecular weight of 472.70. It has a CAS number of 19533-92-7. The compound is a natural triterpenoid derivative.
|
| Toxicity/Toxicokinetics |
The toxicity profile of lup-20(29)-en-28-oic acid, 2,3-dihydroxy- is not well documented. As a natural product, it is expected to have a moderate safety profile, but comprehensive toxicological studies are lacking.
|
| References |
|
| Additional Infomation |
2α,3β-Dihydroxy-20(29)-Lupin-28-acid is a pentacyclic triterpenoid compound, which is betulinic acid with an additional α-hydroxyl group at the 2-position. It has been isolated from Breynia fruticosa. It is a plant metabolite. It is a pentacyclic triterpenoid compound and a dihydroxy monocarboxylic acid. It is functionally related to betulinic acid. It is derived from the hydride of lupinane. Alfithoic acid has also been reported in Rosa woodsii, Streptomyces pristinaespiralis, and other organisms with relevant data.
Lup-20(29)-en-28-oic acid, 2,3-dihydroxy- is a natural triterpenoid with pharmacological activities. It is a derivative of betulinic acid and is used in research on cancer, inflammation, and infectious diseases. |
| Molecular Formula |
C30H48O4
|
|---|---|
| Molecular Weight |
472.69972
|
| Exact Mass |
472.355
|
| CAS # |
19533-92-7
|
| PubChem CID |
12305768
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
566.4±30.0 °C at 760 mmHg
|
| Flash Point |
310.4±21.1 °C
|
| Vapour Pressure |
0.0±3.5 mmHg at 25°C
|
| Index of Refraction |
1.546
|
| LogP |
7.76
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
34
|
| Complexity |
894
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@H]4[C@]([C@@]3(CC2)C)(CC[C@@H]5[C@@]4(C[C@H]([C@@H](C5(C)C)O)O)C)C)C(=O)O
|
| InChi Key |
PFCVZKFJHRCLCC-PGOIBATFSA-N
|
| InChi Code |
InChI=1S/C30H48O4/c1-17(2)18-10-13-30(25(33)34)15-14-28(6)19(23(18)30)8-9-22-27(5)16-20(31)24(32)26(3,4)21(27)11-12-29(22,28)7/h18-24,31-32H,1,8-16H2,2-7H3,(H,33,34)/t18-,19+,20+,21-,22+,23+,24-,27-,28+,29+,30-/m0/s1
|
| Chemical Name |
(1R,3aS,5aR,5bR,7aR,9R,10R,11aR,11bR,13aR,13bR)-9,10-dihydroxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~105.78 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (10.58 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1155 mL | 10.5775 mL | 21.1551 mL | |
| 5 mM | 0.4231 mL | 2.1155 mL | 4.2310 mL | |
| 10 mM | 0.2116 mL | 1.0578 mL | 2.1155 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
